MariTide vs Amycretin: Amgen's GIP-Antagonist Bet vs Novo's Amylin Bet
By FormBlends Medical Team · Last updated: April 25, 2026
MariTide is the more unconventional mechanism bet. Amycretin is the more intuitive platform bet. Both are Phase 3, but they represent two very different ideas about where late-stage obesity drug design should go next.
How to Use This Comparison
Use this comparison as a decision aid, not a prescription shortcut. MariTide combines GLP-1 agonism with GIP antagonism, while amycretin combines GLP-1 with amylin. MariTide (maridebart cafraglutide) is usually a better fit for readers looking for a differentiated late-stage mechanism rather than another familiar incretin combo, while Amycretin (Zenagamtide) is usually a better fit for readers who think the market may reward a more intuitive next-wave combination story. Cost also matters: MariTide (maridebart cafraglutide) is listed at Trial-stage asset; launch pricing unknown, while Amycretin (Zenagamtide) is listed at Trial-stage asset; launch pricing unknown. Because this comparison is framed as an either-or decision, the safety question is which option fits your health history, side-effect tolerance, and access path.
PubMed evidence trail
Research sources used to frame this page
For MariTide vs Amycretin: Amgen's GIP-Antagonist Bet vs Novo's Amylin Bet, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
MariTide vs Amycretin: Amgen's GIP-Antagonist Bet vs Novo's Amylin Bet should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Head-to-Head Comparison
MariTide (maridebart cafraglutide)
Pipeline Compound
Strengths
- Phase 3 asset from Amgen with a genuinely different GLP-1 plus GIP-antagonist angle
- The mechanism makes it one of the more intellectually interesting late-stage programs
- Could matter if the market wants differentiation beyond the usual incretin stacking
Weaknesses
- The more unusual mechanism also creates more market education work
- Needs to prove its commercial fit against simpler stories
Best For
Readers looking for a differentiated late-stage mechanism rather than another familiar incretin combo.
Typical Cost
Trial-stage asset; launch pricing unknown
Amycretin (Zenagamtide)
Pipeline Compound
Strengths
- Phase 3 program with strong sponsor support from Novo
- GLP-1/amylin is easier to explain as a satiety-focused next step
- Feels more naturally aligned with Novo's broader obesity platform
Weaknesses
- Still needs to prove it is more than a portfolio extension
- Commercially it may be judged against CagriSema as much as against external rivals
Best For
Readers who think the market may reward a more intuitive next-wave combination story.
Typical Cost
Trial-stage asset; launch pricing unknown
Key Differences
- 1MariTide combines GLP-1 agonism with GIP antagonism, while amycretin combines GLP-1 with amylin
- 2Amgen is betting on a more contrarian mechanism story; Novo is pushing a more intuitive satiety-extension story
- 3Both are late-stage, but the education burden is probably higher for MariTide
- 4Amycretin may fit more neatly into current market language, while MariTide may stand out more if it works
Frequently Asked Questions
What is the difference between MariTide (maridebart cafraglutide) and Amycretin (Zenagamtide)?
MariTide combines GLP-1 agonism with GIP antagonism, while amycretin combines GLP-1 with amylin. Amgen is betting on a more contrarian mechanism story; Novo is pushing a more intuitive satiety-extension story.
Which is more effective, MariTide (maridebart cafraglutide) or Amycretin (Zenagamtide)?
MariTide is the more unconventional mechanism bet. Amycretin is the more intuitive platform bet. Both are Phase 3, but they represent two very different ideas about where late-stage obesity drug design should go next.
How much does MariTide (maridebart cafraglutide) cost compared to Amycretin (Zenagamtide)?
MariTide (maridebart cafraglutide) typically costs Trial-stage asset; launch pricing unknown, while Amycretin (Zenagamtide) typically costs Trial-stage asset; launch pricing unknown.
Who should choose MariTide (maridebart cafraglutide) over Amycretin (Zenagamtide)?
MariTide (maridebart cafraglutide) is best for: Readers looking for a differentiated late-stage mechanism rather than another familiar incretin combo.. Amycretin (Zenagamtide) is best for: Readers who think the market may reward a more intuitive next-wave combination story..
Ready to get started?
Connect with a licensed provider who can help you decide between MariTide (maridebart cafraglutide) and Amycretin (Zenagamtide) based on your goals, health history, and budget.